TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01211418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Meditation
Description: Stage 1: Treatment Engagement and Detoxification. Use 6 breaths/minute as near resonant-frequency.~Stage 2: Recovery and transition by reducing craving and irritability. Wk 3: introduce 16-mins IM. Wk 4: RFB \& IM as a coping tool. Wk 5: add guided imagery into IM. Wk 6: review and catch-up if miss any prior sections.~Stage 3: Revitalization and Relapse Prevention. Wk 7: customize guided imagery. Wk 8: introduce full version of IM. Wk 9: techniques of handling random thoughts during meditation and learn to separate thoughts from action. Wk 10: how to use IM techniques to handle different relapse triggers. Wk 11: different ways to integrate IM technique into daily life. Wk 12: review, feedback, and provide local sources for more meditation practice and study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Counseling
Description: NT is a procedure in which the therapist refrains from directing the client, but instead reflects back to the client what the latter has said. NT is chosen for this study to control for non-specific effects that show to contribute to outcome such as therapeutic alliance and therapist competency.~The protocol for the individualized NT will mirror the layout of IM therapy -12 weekly meetings, 30 minutes each. Subjects in NT group will be instructed to do Diaphragmatic Breathing (DB) exercise and will be given assigned homework (writing journal) and track progress. DB is incorporated into the NT as treatment providing non-specific effects associated with attention and homework completion.
Study: NCT02897986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination
Study: NCT03668236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic crystalloids
Description: Types of fluid to be used in both intervention groups:~* IV fluids given for circulatory impairment: Only isotonic crystalloids are to be used as per the Scandinavian guideline for fluid resuscitation~* Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used~* Fluids used for dehydration: Water or isotonic glucose should be used~* Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency, including water in the case of severe hypernatremia~* Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic crystalloids
Description: Types of fluid to be used in both intervention groups:~* IV fluids given for circulatory impairment: Only isotonic crystalloids are to be used as per the Scandinavian guideline for fluid resuscitation~* Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used~* Fluids used for dehydration: Water or isotonic glucose should be used~* Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency, including water in the case of severe hypernatremia~* Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy
Study: NCT01229735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: 250 mg and 500 mg levetiracetam tablet 1000 mg/day (500 mg bid) levetiracetam (maximum to 3000 mg/day) Duration: maximum 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: 25 mg and 100 mg topiramate tablet 100 mg/day(50 mg bid) topiramate (maximum to 400 mg/day) Duration: maximum 52 weeks
Study: NCT02331368

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140-200 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 5-15 mg/day starting 45-90 days post-transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: 200 mg/day every 3 weeks starting day +14 post-transplant for a total of 9 doses.
Study: NCT03912441

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-147
Description: Bispecific anti-HER2 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-147
Description: Bispecific anti-HER2 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-147
Description: Bispecific anti-HER2 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-147
Description: Bispecific anti-HER2 monoclonal antibody
Study: NCT02218125

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Mosaic
Description: 0.5 mL (1x10E8 pfu) MVA Mosaic (comprised of MVA Mosaic 1 and MVA Mosaic 2 mixed in a 1:1 ratio before administration) will be administered by intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Mosaic
Description: 0.5 mL (1x10E8 pfu) MVA Mosaic (comprised of MVA Mosaic 1 and MVA Mosaic 2 mixed in a 1:1 ratio before administration) will be administered by intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL Sodium Chloride Injection USP, 0.9%will be administered by intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL Sodium Chloride Injection USP, 0.9%will be administered by intramuscular (IM) injection.
Study: NCT04481321

Intervention type: BIOLOGICAL
Intervention: Biological/Vaccine
Study: NCT04596228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899
Description: Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
Study: NCT01663935

Intervention type: DRUG
Group type: OTHER
Intervention: Levodopa/carbidopa
Description: This study will have an intent to treat goal. Anyone that fits the inclusion criteria for the study will be entered and receive study drug.
Study: NCT04131153

Intervention type: PROCEDURE
Group type: OTHER
Intervention: radiofrequency ablation
Description: Conventional radiofrequency ablation
Study: NCT03671252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: Irinotecan165 mg/m2、Oxaliplatin85 mg/m2、Left-calcium leucovorin 200mg/㎡，Intravenous infusion，first day. Then, 5-FU 1600 mg/m2/d×2 continuous intravenous infusion（total 3200 mg/m2，infusion 46 hours）in the next two days. Repeat every 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: XELOX consisting of 130 mg/m2 oxaliplatin administered intravenously on day 1 and 1,000 mg/m2 capecitabine administered orally twice daily on days 1-14 for a 3-week cycle.
Study: NCT02831647

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AYMES PRAGUE
Description: AYMES PRAGUE is a ready to drink, high energy, low volume oral nutritional supplement drink. It provides 300 kcal and 12g protein per 125ml serving. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision. It is not designed as a sole source of nutrition.
Study: NCT01712737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Study: NCT01041183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous ramosetron
Description: 0.3 mg IV ramosetron (group I)
Study: NCT03671252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: XELOX consisting of 130 mg/m2 oxaliplatin administered intravenously on day 1 and 1,000 mg/m2 capecitabine administered orally twice daily on days 1-14 for a 3-week cycle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy
Description: Chemotherapy: oral capecitabine（1650 mg/m2）twice daily during radiotherapy without weekend breaks.~Radiation: Radiation therapy is administered via intensity-modulated radiation therapy (IMRT) with a linear accelerator, 6MV-X ray. The patients are scheduled to receive a GTV expanding 6mm to form PTV1 and CTV expanding 6mm to form PTV2. The dose of PTV1 is 50Gy/25 times for 35 days and the dose of PTV2 is 45Gy/25 times for 35 days. Patients were treated in consecutive days per week for a total of 5 weeks.
Study: NCT01041183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral ramosetron
Description: 0.1 mg oral ramosetron (group II)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral and IV ramosetron
Description: 0.1 mg oral ramosetron plus 0.3 mg IV ramosetron (group III).
Study: NCT02834650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac MRI with contrast
Description: Cardiac MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac MRI with contrast
Description: Cardiac MRI
Study: NCT03671252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Chemotherapy: oral capecitabine（1650 mg/m2）twice daily during radiotherapy without weekend breaks.~Radiation: Radiation therapy is administered via intensity-modulated radiation therapy (IMRT) with a linear accelerator, 6MV-X ray. The patients are scheduled to receive a GTV expanding 6mm to form PTV1 and CTV expanding 6mm to form PTV2. The dose of PTV1 is 50Gy/25 times for 35 days and the dose of PTV2 is 45Gy/25 times for 35 days. Patients were treated in consecutive days per week for a total of 5 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TME operation
Description: TME operation
Study: NCT02615418

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIBS system for evaluation and treatment utilizing non invasive brain stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NIBS system for evaluation and treatment utilizing non invasive brain stimulation
Study: NCT01882387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA127
Description: Injection, 300mcg/kg/day for 28 days
Study: NCT04573790

Intervention type: PROCEDURE
Intervention: eFONA
Description: Surgical Tracheotomy

Intervention type: PROCEDURE
Intervention: eFONA
Description: Surgical Tracheotomy
Study: NCT03727971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab Injection
Description: The treatment is initiated with one injection with weight and serum-immunoglobulin E balanced omalizumab. After omalizumab treatment at ovulation it will again be collected material (blood samples, sputum, secretion of the vagina, secretion of the rectum, secretion of the uterus, microbiota). If no pregnancy has occurred after first IVF cycle, this will be repeated for 3 consecutive IVF cycles in total or until pregnancy has occurred.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: The treatment is initiated with one injection with placebo. After placebo injection treatment at ovulation it will again be collected material (blood samples, sputum, secretion of the vagina, secretion of the rectum, secretion of the uterus, microbiota). If no pregnancy has occurred after first IVF cycle, this will be repeated for 3 consecutive IVF cycles in total or until pregnancy has occurred.
Study: NCT02063984

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Outpatient Treatment (IOP) + Contingency Management (CM)
Description: Multiple group sessions weekly, one individual counseling session weekly with teen to review and discuss contingency management abstinence-based incentives

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Outpatient Treatment (IOP) + Contingency Management (CM)
Description: Multiple group sessions weekly, one individual counseling session weekly with teen to review and discuss contingency management abstinence-based incentives

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working Memory Training
Description: 25 computer-delivered sessions of neurocognitive training
Study: NCT00945373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium dobesilate
Description: 2.5% gel
Study: NCT04018703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: loading dose 30-50ug/kg followed by continuous infusion 10-30ug/kg/h
Study: NCT02521740

Intervention type: OTHER
Intervention: Research questionnaires, blood sample
Description: assessment of health (frailty, nutrition, physical performance, depression, burden, sense of coherence, caregiver reaction)

Intervention type: OTHER
Intervention: Research questionnaires, blood sample
Description: assessment of health (frailty, nutrition, physical performance, depression, burden, sense of coherence, caregiver reaction)
Study: NCT00973622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS) 10 Hertz (Hz)
Description: All participants will receive 90 10-pulse trains of 1 sec duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS) 10 Hertz (Hz)
Description: All participants will receive 90 10-pulse trains of 1 sec duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS) 20Hz
Description: All participants will receive 45 20-pulse trains of 1 second duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS) 20Hz
Description: All participants will receive 45 20-pulse trains of 1 second duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM repetitive transcranial magnetic stimulation (rTMS)
Description: The look and sound of active rTMS is reproduced with the same coil used in the active conditions. The magnetic field in the sham coil is markedly attenuated at only 5% of stimulator output. The feel of active stimulation will be reproduced by delivering monophasic current pulses to the left, frontalis muscle with a Isolated Stimulator and two carbon rubber electrodes. Smokers will receive Sham rTMS in both the nicotine-satiated and nicotine-withdrawal conditions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM repetitive transcranial magnetic stimulation (rTMS)
Description: The look and sound of active rTMS is reproduced with the same coil used in the active conditions. The magnetic field in the sham coil is markedly attenuated at only 5% of stimulator output. The feel of active stimulation will be reproduced by delivering monophasic current pulses to the left, frontalis muscle with a Isolated Stimulator and two carbon rubber electrodes. Smokers will receive Sham rTMS in both the nicotine-satiated and nicotine-withdrawal conditions.
Study: NCT01937481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Food Friends
Description: The Food Friends is a research-based preschool program designed to address childhood obesity by establishing healthful eating and physical activity behaviors in preschool-aged children. The Food Friends: Fun With New Foods (12 weeks) focuses on helping children increasing children's willingness to try new foods and The Food Friends: Get Movin' With Mighty Moves (18 weeks) aims to enhance preschoolers' gross motor skill development. In effort to sustain the preschool behavior changes, the messages from The Food Friends® (Super Taster and Mighty Mover) will be extended into early elementary school through a 'booster' program. The booster program will consist of a kindergarten and 1st grade curriculum with 5 monthly units.
Study: NCT01610206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will receive gemcitabine 1000 mg/m2 administered weekly on days 1 and 8 (30 minutes IV infusion) of each cycle for up to 6 cycles. Each cycle is 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Patients will receive gemcitabine 1000 mg/m2 administered weekly on days 1 and 8 (30 minutes IV infusion) of each cycle for up to 6 cycles. Each cycle is 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Patients will receive pazopanib 800mg PO daily on days 1-21 of treatment cycles
Study: NCT00945373

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulsed dye laser
Description: All study patients will be treated with 595 nm PDL (Vbeam, Candela Corp, Wayland, Mass) with an initial test spot using a fluence of 10 J/cm2, 7-mm spot size and 1.5-ms pulse duration. Based on the biologic response of the test area, the fluence will accordingly be adjusted up or down to find a fluence that produces a transient purpuric effect for a few seconds only.
Study: NCT02413476

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted Gastrectomy(RAG)
Description: Surgical procedure will be performed with da vinci Surgical System.The type of reconstruction will be selected according to the surgeon's experience.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic-assisted Gastrectomy(LAG)
Description: Surgical procedure will be performed with laparoscopic techniques.The type of reconstruction will be selected according to the surgeon's experience.
Study: NCT01527877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Patients will be instructed to take BKM120 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day. The patient will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. If vomiting occurs no attempt should be made to replace the dose.~• BKM120 should be taken 1-hour following a light meal. Please note that patients must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to the first dose of study drug and during the entire study treatment period due to potential CYP3A4 interaction. Regular orange juice is allowed.
Study: NCT03019757

Intervention type: RADIATION
Intervention: DaTscan
Description: A functional imaging of the dopamine transporter using the radioligand \[123I\]FP-CIT

Intervention type: RADIATION
Intervention: DaTscan
Description: A functional imaging of the dopamine transporter using the radioligand \[123I\]FP-CIT

Intervention type: RADIATION
Intervention: DaTscan
Description: A functional imaging of the dopamine transporter using the radioligand \[123I\]FP-CIT

Intervention type: RADIATION
Intervention: F18-AV-45
Description: A brain scan to to measure the extent of amyloid deposition

Intervention type: RADIATION
Intervention: F18-AV-45
Description: A brain scan to to measure the extent of amyloid deposition

Intervention type: RADIATION
Intervention: F18-AV-45
Description: A brain scan to to measure the extent of amyloid deposition

Intervention type: RADIATION
Intervention: FDG-PET
Description: a brain scan measuring total and regional cerebral glucose metabolism wtih positron emission tomographs with 2-(18F)

Intervention type: RADIATION
Intervention: FDG-PET
Description: a brain scan measuring total and regional cerebral glucose metabolism wtih positron emission tomographs with 2-(18F)

Intervention type: RADIATION
Intervention: FDG-PET
Description: a brain scan measuring total and regional cerebral glucose metabolism wtih positron emission tomographs with 2-(18F)

Intervention type: GENETIC
Intervention: APOE genotype
Description: 10 ml of whole blood will be drawn and shipped to Athena Diagnostics for genetic testing.

Intervention type: GENETIC
Intervention: APOE genotype
Description: 10 ml of whole blood will be drawn and shipped to Athena Diagnostics for genetic testing.

Intervention type: GENETIC
Intervention: APOE genotype
Description: 10 ml of whole blood will be drawn and shipped to Athena Diagnostics for genetic testing.

Intervention type: PROCEDURE
Intervention: Polysomnogram
Description: Overnight sleep study
Study: NCT01148693

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gentamicin
Description: 10mg per 10ml of contrast media
Study: NCT03019757

Intervention type: PROCEDURE
Intervention: Polysomnogram
Description: Overnight sleep study

Intervention type: PROCEDURE
Intervention: Polysomnogram
Description: Overnight sleep study

Intervention type: BEHAVIORAL
Intervention: Clinical Assessment
Description: Clinical assessments include cognitive, behavioral, and motor evaluations

Intervention type: BEHAVIORAL
Intervention: Clinical Assessment
Description: Clinical assessments include cognitive, behavioral, and motor evaluations

Intervention type: BEHAVIORAL
Intervention: Clinical Assessment
Description: Clinical assessments include cognitive, behavioral, and motor evaluations
Study: NCT00133263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Bereavement Care
Description: a standardized bereavement intervention in Primary Care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: the current bereavement care in primary care
Description: the non-standardized bereavement care that usually provided family physicians in primary care
Study: NCT01148693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gentamicin
Description: 10mg per 10ml of contrast media
Study: NCT00648258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 10 mg tablet by mouth once daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: naproxen 500 mg capsule by mouth twice daily for 6 weeks
Study: NCT02474303

Intervention type: DRUG
Group type: OTHER
Intervention: Truvada
Description: Demonstration Study